Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Boehringer Ingelheim Refocuses PDE9 Inhibition Brain Research on Schizophrenia

americanpharmaceuticalreviewFebruary 12, 2018

Tag: Boehringer Ingelheim , Alzheimer's Disease , AD

PharmaSources Customer Service